Illumina Releases Next-Generation Benchtop Sequencers

Illumina Releases Next-Generation Benchtop Sequencers

Highlights
  • Illumina has introduced the MiSeq i100 Series, a benchtop next-generation sequencing system
  • The sequencing system is available in two configurations: the MiSeq i100 and the MiSeq i100 Plus

Illumina, a global leader in DNA sequencing and array-based technologies, has introduced the MiSeq™ i100 Series of sequencing equipment that offers benchtop speed along with simplicity. The MiSeq i100 and MiSeq i100 Plus Systems provide a cost-effective solution for gaining significant insights. The systems enable labs to sequence on demand and analyse samples on the same day.

The MiSeq i100 Series improves the MiSeq System’s legacy with the NovaSeq™X Series technology’s newer version. It uses room-temperature storage and shipping, which provides greater flexibility for project planning and execution. The MiSeq i100 Plus can run as much as 100 million single-end reads per run while the MiSeq i100 configurations can run 25 million. The MiSeq i100 sequencing system is expected to be rolled out in 2025. This sequencing equipment will have the following benefits:

  • Room-temperature reagent shipping and storage reduce the need for a cold chain and enable on-demand sequencing
  • Reduction in packaging waste by 85%, which reduces carbon footprint
  • Reduced run times by up to four hours, with same-day results
  • Cost-effective consumables enable affordable sequencing
  • Up to 18 proven workflows across 10 applications
  • Provides efficient operations for various sequencing experience levels

MiSeq i100 also offers push-button workflows for microbiology and infectious disease/oncology, providing metrics directly on the instrument or via cloud- based DRAGEN™ genomic data analysis, reducing bioinformatics expertise requirements.

Related post

AstraZeneca’s DatroWay Delivers Breakthrough in Advanced Breast Cancer Survival

AstraZeneca’s DatroWay Delivers Breakthrough in Advanced Breast Cancer Survival

Highlights: DatroWay, a new innovation by AstraZeneca, boosts survival odds among advanced breast cancer patients DatroWay utilises ADC that delivers high-precision…
What is the link between Long Covid and The Mysterious Brain Fog?

What is the link between Long Covid and The…

Highlights: AMPAR receptors may explain the onset of brain fog among those affected by long Covid AMPARs also provide explanation for…
Update on WHO’s Triple Billion Targets

Update on WHO’s Triple Billion Targets

Highlights: WHO progressing toward Triple Billion targets focused on health, UHC, and emergency protection 5 billion people expected to benefit by…